Table 1.
Study 206 (Single-Agent Eribulin in HER2− MBC): demographics and baseline characteristics
| With prior anthracycline (n = 27) | With prior taxane (n = 26) | With prior anthracycline and taxane (n = 20) | Without prior anthracycline or taxane (n = 23) | |
|---|---|---|---|---|
| Female, n (%) | 27 (100) | 26 (100) | 20 (100) | 23 (100) |
| Age (years) | ||||
| Mean (SD) | 55 (10) | 55 (11) | 55 (11) | 61 (11) |
| Age group, n (%) | ||||
| <50 years | 9 (33) | 9 (35) | 7 (35) | 3 (13) |
| 50–65 years | 13 (48) | 11 (42) | 8 (40) | 10 (43) |
| >65 years | 5 (19) | 6 (23) | 5 (25) | 10 (43) |
| Age at diagnosis (years) | ||||
| Mean (SD) | 49 (10) | 52 (11) | 52 (10) | 57 (11) |
| Estrogen receptor (ER) status, n (%) | ||||
| + | 17 (63) | 13 (50) | 11 (55) | 22 (96) |
| – | 10 (37) | 13 (50) | 9 (45) | 1 (4) |
| Progesterone receptor (PR) status, n (%) | ||||
| + | 18 (67) | 13 (50) | 12 (60) | 19 (83) |
| – | 9 (33) | 13 (50) | 8 (40) | 4 (17) |
| HER2 status, n (%) | ||||
| + | 0 | 0 | 0 | 0 |
| – | 27 (100) | 26 (100) | 20 (100) | 23 (100) |
SD standard deviation